Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Target BCMA chimeric antigen receptor, nucleic acid sequence, carrier and application

A nucleic acid sequence, subject technology, applied in the direction of targeting specific cell fusion, peptides containing localization/targeting motifs, and antibody medical components, etc. Tumor targeting, good therapeutic effect, and the effect of enhancing binding capacity

Pending Publication Date: 2019-12-06
浙江煦顼技术有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In view of the problem that existing myeloma agents cannot lead to durable remission, the present invention provides a BCMA-targeting chimeric antigen receptor that has the ability to specifically kill plasmacytoma from myeloma patients. The function of myeloma cells, thus solving the problem of myeloma patients who cannot achieve durable remission

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Target BCMA chimeric antigen receptor, nucleic acid sequence, carrier and application
  • Target BCMA chimeric antigen receptor, nucleic acid sequence, carrier and application
  • Target BCMA chimeric antigen receptor, nucleic acid sequence, carrier and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0144] The present disclosure is further described by reference to the following examples. These examples are provided for the purpose of illustration only and are not intended to be limiting unless otherwise stated. Accordingly, the present disclosure should in no way be construed as limited to the following examples, but rather should be construed to encompass any and all variations which become apparent as a result of the teaching presented herein.

[0145] Construction of K562 cell line expressing antigen

[0146] K562 cells were transduced with lentivirus containing the nucleic acid sequence encoding BCMA to establish target tumor cell lines. Lentiviruses include the IRES-mCherry (red) construct, which encodes red fluorescence to confirm antigen expression. Red fluorescence signals were observed from these cell lines, indicating that the target solid tumor cell lines were successfully established ( figure 2 ). The technology of constructing cell lines can be found in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a target BCMA chimeric antigen receptor, a nucleic acid sequence, a carrier and an application, and a composition and a method for treating cancers using CAR cells. The composition comprises the isolated nucleic acid sequence for coding a CAR, wherein the CAR comprises an extracellular structure domain, a transmembrane structure domain and an intracellular structure domain; the extracellular structure domain is bound with a BCMA; the isolated nucleic acid sequence includes the nucleic acid sequence as shown in SEQ ID NO: 1, 2 or 9; the intracellular structure domain comprises a co-stimulation signal conduction region; and the co-stimulation signal conduction region comprises molecules selected from CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-related antigen-1(LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and any combination thereof.

Description

technical field [0001] The present disclosure relates to modified cells and uses, in particular to compositions and methods for treating cancer using BCMA-targeted chimeric antigen receptor (CAR) cells. Background technique [0002] B-cell maturation antigen (BCMA), or CD269, is a B-cell surface molecule. BCMA is composed of 184 amino acids, its intracellular region contains 80 amino acids, and its extracellular region is very short, with only one carbohydrate recognition domain. In normal tissues, BCMA is expressed on the surface of mature B cells and plasma cells, and plays an important role in maintaining the survival of plasma cells. [0003] Chimeric antigen receptor-modified T cells (CAR T) technology is a revolutionary approach to treating cancer. On August 10, 2011, on the basis of more than 20 years of research by scientists around the world, American scientists cured two patients with advanced chronic lymphocytic leukemia by using the patient's modified T cells, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/62C12N5/10C07K19/00A61K39/00A61P35/00
CPCC07K16/2878C07K14/7051C12N5/0636A61K39/001102A61P35/00C07K2319/03C07K2319/33C12N2510/00
Inventor 曹志远肖磊吴昭彭君凯刘婧睿
Owner 浙江煦顼技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com